The effect of various hepatoprotectors on pathological syndromes in chronic liver diseases and determination of the specific gravity of drug groups
DOI:
https://doi.org/10.47494/mesb.v6i.105Keywords:
chronic hepatitis, cirrhosis, hepatoprotector, cholestasis, cytolytic syndromeAbstract
Chronic hepatitis, cirrhosis of the liver and their consequences remain a global medical and social problem in the world. In the clinical practice of previous years, a variety of drugs were used as means of pathogenetic therapy, many of which turned out to be ineffective and went out of use. At the same time, widely known data on the ability of liver tissue to regenerate allow a rather high assessment of the prospects and potential possibilities of pathogenetic therapy of chronic hepatitis and cirrhosis using hepatoprotectors [1.2.5].
Drug therapy for patients with liver pathology should always be as economical as possible. In each case, it is necessary to compare the degree of necessity of prescribing the drug and the potential danger of its side effects. In the treatment of patients with liver diseases, polypharmacy is extremely undesirable, and the prescribed doses, as a rule, should not exceed the average therapeutic and course [9.10.12].
Downloads
References
. Diseases of the liver and biliary tract. Manual for Doctors / Ed. V.T. Ivashkina. 2-е изд. - M.iOOO " Ed. house "M-Vesti», 2005.-536 р.
Zollner G., Marschall H.U., Wagner et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis pathogenetic and'' therapeutic considerations // Mol. Pharm. 2006. - Vol. 3(3). - P. 231-251.
LindorK.D., TalwalkarJ.A.,editors. Cholestatic liver disease. New Jersey: Humana Press, 2008, - 188 p.
Makino and Tanaka H. From a choleric drug to an immunomodulator: a historical review of the use of ursodeoxycholic acid Medicines of Ukraine.-2009.- №6.- Р.102-105.
Nurboyev F., Umarov F. Comparative АВС/VEN analysis of medicine used for treatment of chronic hepatitis and hepatic cirrhosis by period 2006-2016 yy. // Medicine and sport —2019—Vol. 2. — P. 46—49
Nurboyev F.E., Umarov F.Kh. Pharmacoeconomic analysis of the costs of hepatoprotectors for the treatment of chronic hepatitis in a hospital setting (retrospective study)// Medicine and sport —2019—Vol. 2. — P.49—52
Nurbaev F.E., Jabborova O.I., Umarov F.Kh., Sultonova L.J. Pharmacoeconomic analysis of the treatment of chronic hepatitis "C"// European journal of pharmaceutical and medical research.— 2019.— Vol. 6 (12).— P. 70—75.
Djabbarova M., Nurboyev F., Qodirova Sh., Umarov F. Comparative characteristics of medicine used for treatment of chronic hepatitis and hepatic cirrhosis //New day in a medicine -2019 - № 4(28) - P.151-153.
Zaretsky M.M., Chernikova N.M., Lobachevskaya T.V. Possibilities of using ursodeoxycholic acid in the treatment of gallstone disease Modern gastroenterology, — 2011. — № 2. —Р.136—140.
Fedosina E.A., Mayevskaya M.V. The use of ursodeoxycholic acid in non-alcoholic and alcoholic steatohepatitis РЖГГК. —2010. —№ 3. — Р.29—36.
Kushnir I.E., Chernova V.M., Solomentsev T.A. Diagnostic criteria and therapeutic approaches for cholestatic liver diseases Acute and urgent conditions in the practice of a doctor.—2013. —№ 2—3.- Р.19—24.
Ivashkin V.T. Gastroenterology: Clinical recommendations.— М., 2008.— 182 р.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Nurbaev Farmon Ergashevich, Umarov Firuz Kholmurodovich, Yuldashova Shakhlo Toyirovna
This work is licensed under a Creative Commons Attribution 4.0 International License.
The work simultaneously licensed under a Creative Commons Attribution 4.0 International License
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
